Sarah Schlesinger, MD was a co-author for the cdx-301 study
She is also the principal investigator for the HIV vaccine.
The three-year, randomized, placebo-controlled, Phase I trial, known as DCVax-001, will enroll 45 healthy HIV-uninfected volunteers in New York City. Investigators will evaluate both the safety and immunogenicity of the vaccine candidate administered at three different doses, along with a fixed dose of an experimental adjuvant called Poly ICLC (Hiltonol) that was designed to activate innate immune responses. The volunteers will receive three subcutaneous vaccinations of either the vaccine candidate or placebo over 12 weeks, and will then be monitored for 12 months.
Researchers at Rockefeller have been working with Celldex Therapeutics, a biotechnology company headquartered in Massachusetts, on the development of the candidate vaccine. Celldex previously developed a vaccine candidate with a mAb fused to DEC-205 to target a tumor-associated antigen known as NY-ESO-1, but this is the first time an AIDS vaccine candidate has been constructed using this technology.
Estimated Enrollment: 45
Study Start Date: May 2010
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Principal Investigator: Sarah Schlesinger, MD The Rockefeller University
There was an update to that trial in Feb, I will be curious to see what they say about this product in May. I use to follow it when I followed Avant. This agent is both a prevention and treatment vaccine if I remember right. There is a nice update from the phrma, pharmaceutical manufacturers research assocation on HIV. Alot of the phrma. org has alot of yearly publication on disease states now that lists many of the agents. You can research the website though and find 1,000 thousands of products and company information on their pipelines, I use it all the time.
Thanks Weight for your summaries of the CLDX pipeline. There are so many opportunities for CLDX...and the growing pipeline has added incredible value that is now becoming appreciated by the marketplace. The high volume growth days and weeks after the share offering coupled with the absence of a period of share weakness following the dilution have catalyzed the recent surge in pps. Consolidation and base formations continue to form each day and the upward trend continues.
This truly is shaping up to be a phenomenal year for Celldex and predictions that Celldex could be the biotech stock of the year 2013 are very possible. Forbes' rating of Celldex right in the middle of the top five biotech stocks in February is a testament to that possibility.
Good luck Longs....things are really shaping up for all of us.